The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Shifting his focus to treatment strategies in myelofibrosis, Naveen Pemmaraju, MD, reviews the current drug armamentarium and explains how it ties into disease modification.

Expert hematologist-oncologist Naveen Pemmaraju, MD, highlights current strategies in diagnosing and stratifying patients with myelofibrosis.

Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

Michael L. Wang, MD, discusses the efficacy of the noncovalent BTK inhibitor pirtobrutinib, as well as safety data from the phase 1/2 BRUIN trial in mantle cell lymphoma.

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.

Shubham Pant, MD, discusses the rationale, trial design, and key efficacy and safety data from an expansion cohort of the phase 2 RAGNAR trial in biliary tract cancers.

Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Sapna Patel, BA, MD, discusses the sequencing of immunotherapy and targeted therapy in BRAF-mutant melanoma.

Dr Somaiah discusses the excitement surrounding novel agents such as CSF1R inhibitors and ULK1/2 inhibitors, and the utility of broad spectrum TKIs such as ripretinib.

Moderately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from the single-arm, phase 2 trial HYPORT-STS.

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

Investigators may have discovered a key detail about renal medullary carcinoma that could have significant ramifications for patients.

During his career, David M. Gershenson, MD, has helped turn ovarian cancer treatment into an evidence-based field and built better therapies through an improved biological understanding of the disease.

Guillermo Garcia-Manero, MD, discusses the exploration of these doublet therapies and what they could mean for the high-risk myelodysplastic syndromes treatment landscape, the difficulties in making strides for patients with relapsed/refractory disease, and the top highlights in myelodysplastic syndromes from the 2022 ASH Annual Meeting.

Elias Jabbour, MD, discusses the evaluation of olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the benefits of considering the whole treatment course, and subgroup analyses from the MAIA trial.

Virginia G. Kaklamani, MD, discusses the ongoing investigation of novel oral SERDs in patients with ER-positive/HER2-negative breast cancer, the remaining unmet needs for this patient population, and ongoing trials aiming to further understand the optimal use of oral SERDs.

Dr Blum discusses renal medullary carcinoma, the lack of approved systemic therapy for these patients, and findings showing a correlation between CA-125 levels and increased tumor burden and treatment response in this disease.

Elias Jabbour, MD, discusses the current and emerging roles of CAR T-cell therapy in B-ALL, emphasizes the importance of testing patients for MRD when determining CAR T-cell treatment strategies, and highlights how obe-cel, with its favorable safety profile, may address unmet needs related to CAR T-cell toxicities.

Olverembatinib elicited encouraging responses and tolerability in US patients with ponatinib-resistant chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and in patients with CML whose tumors have a T315I mutation.

The addition of magrolimab to azacitidine and venetoclax produced high complete response rates and was well tolerated as first-line therapy in patients with high-risk de novo and secondary acute myeloid leukemia regardless of TP53 mutation status.

The addition of 1 year of everolimus to adjuvant endocrine therapy did not demonstrate a statistically significant improvement in invasive disease-free survival or overall survival in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer.

Sapna Patel, MD, discusses the evaluation of adjuvant nivolumab plus ipilimumab in stage IV metastatic melanoma with no evidence of disease.

Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.

For many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.

Elias Jabbour, MD, discusses the importance of testing for minimal residual disease when determining optimal treatment strategies for patients with B-cell acute lymphoblastic leukemia.

Sapna Patel, MD, reviews several key studies across stages of melanoma and emerging targeted therapies for patients with BRAF mutations.

Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.

Jason Westin, MD, FACP, discusses reasons to refer patients with diffuse large B-cell lymphoma to second-line CAR T-cell therapy, CAR T-cell eligibility criteria, and high-risk disease features that may further support the use of CAR T-cell therapy in the second line, rather than chemotherapy.

The combination of sotigalimab and pembrolizumab showed encouraging antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.